VYGR News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

VY

Mkt Cap

$116.8M

Volume

464.02K

Next Earnings

November 9th

Loading chart

VY

VYGRVoyager Therapeutics, Inc. Common Stock

VYGR

Pay with—

Available Balance0.00

VY

Mkt Cap

$126.9M

Volume

464.02K

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

J&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical DeclineJohnson & Johnson discontinued its Phase 2b AuTonomy study of posdinemab after the drug failed to show statistical significance in slowing clinical decline for early Alzheimer's disease patients.Benzinga · Nov 25, 2025

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE ApproachVoyager Therapeutics expanded its Alzheimer's disease franchise by introducing a new gene therapy program targeting APOE, complementing existing tau and amyloid assets. The program aims to reduce APOE4 variant expression while delivering the protective APOE2 variant using an innovative IV-delivered TRACER capsid.GlobeNewswire Inc. · Jul 16, 2025

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy PublicationVoyager Therapeutics published data in Molecular Therapy demonstrating the ability of a novel AAV capsid, VCAP-102, to cross the blood-brain barrier and transduce various brain regions in rodents and non-human primates. The company also highlighted its next-generation CNS capsids and non-viral delivery approaches.GlobeNewswire Inc. · May 15, 2025

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025Voyager Therapeutics presented new preclinical data on its tau-targeting gene therapy VY1706 and anti-tau antibody VY7523 at the AD/PD™ 2025 conference. The data showed promising results in reducing tau levels and inhibiting tau spread in animal models, supporting the potential of these programs for the treatment of Alzheimer's disease.GlobeNewswire Inc. · Mar 31, 2025

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating ResultsVoyager Therapeutics reported progress in its tau silencing gene therapy VY1706 and anti-tau antibody VY7523 programs for Alzheimer's disease. The company also extended its cash runway into mid-2027 by discontinuing its VY9323 program for ALS.GlobeNewswire Inc. · Mar 11, 2025

Kirby McInerney LLP Announces Investigation Against Voyager Therapeutics, Inc. (VYGR) on Behalf of InvestorsKirby McInerney LLP is investigating potential claims against Voyager Therapeutics, Inc. (VYGR) due to emerging preclinical data indicating the siRNA payload component of VY9323 does not meet the company's standards, resulting in a narrowed therapeutic window and the decision to not file an IND application for VY9323 in mid-2025.GlobeNewswire Inc. · Feb 19, 2025

Voyager Therapeutics to Present at Multiple Upcoming Investor ConferencesVoyager Therapeutics, a biotechnology company, announced its participation in several upcoming investor conferences, including discussions on genetic medicines and fireside chats.GlobeNewswire Inc. · Nov 6, 2024

Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsightThe rising incidence of Alzheimer's and other tau-related disorders is driving the demand for tau-targeting therapies. Innovative approaches, particularly small molecules that inhibit tau aggregation, are at the forefront of R&D. Increased funding is accelerating advancements in neurodegenerative disease treatments, positioning tau inhibitors as a key market driver.GlobeNewswire Inc. · Oct 14, 2024

Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR TechnologyThe global gene therapy market is expected to grow significantly, driven by technological advancements, increased R&D investment, and the rising prevalence of genetic disorders. Key players in the market are focusing on developing transformative gene therapy platforms and expanding their capabilities through strategic collaborations and acquisitions.GlobeNewswire Inc. · Aug 30, 2024

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswireVoyager Therapeutics, a biotechnology company, has entered into an employment agreement with Eric Hall, Ph.D., M.B.A., granting him a non-qualified stock option and restricted stock units as an inducement to join the company as the new Chief Financial Officer.GlobeNewswire Inc. · Jul 23, 2024

to start trading

VY

VYGRVoyager Therapeutics, Inc. Common Stock

VYGR

Pay with—

Available Balance0.00

Your PositionYou don't own any VYGR yet.

Related Tickers

Earnings